{"nctId":"NCT00450450","briefTitle":"Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases","startDateStruct":{"date":"2007-12-31","type":"ACTUAL"},"conditions":["Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Myelodysplastic Syndromes","Chronic Phase Chronic Myelogenous Leukemia","de Novo Myelodysplastic Syndromes","Juvenile Myelomonocytic Leukemia","Previously Treated Myelodysplastic Syndromes","Recurrent Childhood Acute Lymphoblastic Leukemia","Secondary Myelodysplastic Syndromes"],"count":27,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Procedure: allogeneic bone marrow transplantation","Other: laboratory biomarker analysis","Biological: filgrastim"]},{"label":"Arm II","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: allogeneic bone marrow transplantation","Other: laboratory biomarker analysis"]}],"interventions":[{"name":"allogeneic bone marrow transplantation","otherNames":["bone marrow therapy, allogeneic","bone marrow therapy, allogenic","transplantation, allogeneic bone marrow","transplantation, allogenic bone marrow"]},{"name":"laboratory biomarker analysis","otherNames":[]},{"name":"filgrastim","otherNames":["Granulocyte Colony-Stimulating Factor","r-metHuG-CSF","G-CSF","Neupogen","NSC #614629"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of hematologic cancer or other disease, including any of the following:\n\n  * Chronic myelogenous leukemia in first or second chronic phase\n  * Acute lymphoblastic leukemia (ALL), meeting any of the following criteria:\n\n    * Relapsed ALL enrolled on a Children's Oncology Group (COG) relapse clinical trial OR received ≥ 1 round of reinduction therapy (4-6 weeks) and 1 round of intensive consolidation chemotherapy (3-6 weeks)\n    * ALL in second complete remission (CR)\\* after a bone marrow, extramedullary, or combined bone marrow and extramedullary relapse\n    * Very high-risk ALL in first CR, defined as any of the following:\n\n      * Philadelphia chromosome-positive ALL\n      * Hypodiploidy (\\< 44 chromosomes)\n      * Mixed lineage leukemia rearrangement\n      * Induction failure\n  * Acute myeloid leukemia in first or second CR\n\n    * Induction therapy must be completed\n  * Juvenile myelomonocytic leukemia\n  * Myelodysplastic syndromes\n* No clinically evident CNS or extramedullary disease\n* No blasts seen on cerebrospinal fluid cytospin\n* Post-relapse reinduction therapy must be completed\n* Not planning to receive reduced-intensity conditioning regimen\n* Not planning to receive a graft that has undergone T-cell depletion\n* No Down syndrome\n* Matched sibling donor must be available and must be enrolled on ASCT0631D companion study\n* Karnofsky performance status (PS) 60-100% (patients \\> 16 years of age) OR Lansky PS 60-100% (patients ≤ 16 years of age)\n* AST or ALT \\< 5 times upper limit of normal for age\n* Bilirubin \\< 2.5 mg/dL (unless due to Gilbert's syndrome)\n* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base on age and/or gender as follows:\n\n  * 0.4 mg/dL (1 month to \\< 6 months of age)\n  * 0.5 mg/dL (6 months to \\< 1 year of age)\n  * 0.6 mg/dL (1 to 2 years of age)\n  * 0.8 mg/dL (2 to \\< 6 years of age)\n  * 1.0 mg/dL (6 to \\< 10 years of age)\n  * 1.2 mg/dL (10 to \\< 13 years of age)\n  * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \\< 16 years of age)\n  * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)\n* Shortening fraction ≥ 27% by echocardiogram OR LVEF ≥ 50% by radionuclide angiogram\n* FEV\\_1, FVC, and DLCO ≥ 60% OR meets the following criteria (for patients unable to cooperate for pulmonary function tests):\n\n  * No evidence of dyspnea at rest\n  * No exercise intolerance\n  * No requirement for supplemental oxygen therapy\n* Not pregnant or nursing\n* No known HIV\n* No known uncontrolled fungal, bacterial, or viral infections\n\n  * Patients acquiring fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT scan\n* No prior allogeneic or autologous stem cell transplantation","healthyVolunteers":false,"sex":"ALL","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Two-year Event-free Survival (EFS)","description":"EFS is defined as relapse or treatment-related mortality (TRM). relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Graft Failure Rate","description":"Primary graft failure is defined as the failure to achieve an absolute neutrophil count of more than 5000 per cubic millimeter for at least three consecutive days by Day +42.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)","description":"Stage III-IV aGVHD is defined as: Stage 0-3 skin, with Stage 2-3 liver, or Stage 2-3 GI; OR Stage 4 skin, liver or GI involvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.69","spread":null},{"groupId":"OG001","value":"15.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated 100-day Transplant Related Mortality (TRM) Percentage","description":"Death in a patient after transplant due to protocol treatment is defined as an TRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)","description":"cGVHD definition is based on BMT CTN MOP SEPT. 2005; outlined in Protocol Appendix III.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.69","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Median Time to Neutrophil Engraftment","description":"Median Time from transplant to neutrophil engraftment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Median Length of Initial Hospitalization","description":"Estimated and compared between randomization arms using the Wilcoxon rank-sum test.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Immune Reconstitution","description":"Summarized graphically. Generalized estimating equation will be used to model the levels as a function of time and randomization assignment and to test the impact of G-CSF stimulation on immune reconstruction.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Infused Nucleated and CD34+ Cell Doses","description":"Compared using the Wilcoxon rank-sum test.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Platelet count decreased","Neutrophil count decreased","White blood cell decreased","Infections and infestations - Other, specify","Mucositis oral"]}}}